314752-65-3

Upstream product

• 40843-55-8 4-([1,1'-biphenyl]-4-yloxy)phenol 
• 592508-77-5 4-(4-allyloxy-phenoxy)-biphenyl 
• 158771-58-5 4-([1,1'-biphenyl]-4-yloxy)benzaldehyde 
• 92-69-3 4-Phenylphenol 

Downstream Products

• 656235-25-5 5-(4-{3-[4-(biphenyl-4-yloxy)-2-propyl-phenoxy]-propoxy}-phenyl)-2-imino-thiazolidin-4-one 
• 592508-54-8 (4-{3-[4-(biphenyl-4-yloxy)-2-propyl-phenoxy]-propoxy}-phenyl)-hydroxy-acetic acid methyl ester 
• 606966-67-0 (3-{3-[4-(biphenyl-4-yloxy)-2-propyl-phenoxy]-propoxy}-phenyl)-hydroxy-acetic acid methyl ester 

Relevant academic research and scientific papers

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.